Skip to main content

Profiles

AllerGen

AllerGen Inc., the Allergy, Genes and Environment Network, is a Canadian not-for-profit organization hosted at McMaster University in Hamilton, Ontario that “promotes the work of Canadian researchers and organizations dedicated to improving the quality of life of people suffering from allergic and related immune diseases.”[1]

COVID-19

AllerGen received significant funding for projects related to the declared COVID-19 pandemic.

  • Received “more than $400,000.00” in funding from the COVID-19 Immunity Task Force “to study how COVID-19 is impacting individuals and families across Canada.”[2]
  • Received “nearly $700,000.00” from the Government of Alberta to measure COVID-19 antibody prevalence among Albertan children at the University of Alberta.[3]
  • AllerGen investigator Dr. Christopher Carlsten received a portion of a $2 million grant from the Michael Smith Foundation for Health Research to study long-term lung impacts of COVID-19, and testing to determine long-term quality of life.[4][5]
  • Received $1.7 million from the Canadian Institutes of Health Research (CIHR) and Research Manitoba to “study how individuals and families across Canada have been impacted directly by COVID-19 infection and indirectly by pandemic-related social and economic upheaval.”[6]

Organization

AllerGen is a partner of Food Allergy Canada[7] and Michael Smith Health Research BC.[8]

Personnel

Name Position Notes
Marshall Beck Digital Initiatives Manager (July 2017-April 2020)[9] NanoMedicines Innovation Network (NMIN), NanoVation Therapeutics, International Freedom of Expression Exchange (IFEX), North American Congress on Latin America (NACLA), Centre for Refugee Studies (CRS)
Deborah Danoff Board member (2007-2016)[10] Marketed Health Products Directorate, National Advisory Committee on Immunization (NACI)
Cathy Jiang Finance Manager[11] NanoMedicines Innovation Network (NMIN)

Activities

AllerGen has provived funding to:

  1. About us. AllerGen. Retrieved January 13, 2022, from http://archive.today/2022.01.13-091923/https://www.allergen.ca/about/ ↩︎

  2. Beck, M. (2020, September 16). CITF awards CHILD Cohort Study more than $400K to study COVID-19 impacts. AllerGen. http://archive.today/2022.01.12-210543/https://www.allergen.ca/citf-awards-child-cohort-study-more-than-400k-to-study-covid-19-impacts/ ↩︎

  3. Beck, M. (2020, September 10). Alberta funds COVID-19 antibody testing among Edmonton children in CHILD Cohort Study. AllerGen. http://archive.today/2022.01.12-210757/https://www.allergen.ca/alberta-funds-covid-19-antibody-testing-among-edmonton-children-in-child-cohort-study/ ↩︎

  4. Beck, M. (2020, June 10). AllerGen investigator receives MSFHR grant for COVID-19 research. AllerGen. http://archive.today/2022.01.12-211230/https://www.allergen.ca/allergen-investigator-receives-msfhr-grant-for-covid-19-research/ ↩︎

  5. COVID-19 Research Response Fund Award Recipients. (2021, April 15). Michael Smith Foundation for Health Research. http://archive.today/2022.01.12-210945/https://web.archive.org/web/20210415143503/https://www.msfhr.org/covid-19-research-response-fund-award-recipients ↩︎

  6. Beck, M. (2020, June 25). CHILD Cohort Study awarded $1.7M to study impacts of COVID-19 on Canadian families. AllerGen. http://archive.today/2022.01.12-211500/https://www.allergen.ca/child-awarded-1-7m-to-study-impacts-of-covid-19-on-canadian-families/ ↩︎

  7. Who we work with. Food Allergy Canada. Retrieved April 18, 2022, from http://archive.today/2022.01.03-024343/https://foodallergycanada.ca/our-impact-advocacy-and-services/about-us/who-we-work-with/ ↩︎

  8. Our Partners. Health Research BC. Retrieved January 20, 2023, from http://archive.today/2023.01.20-212749/https://healthresearchbc.ca/our-partners/ ↩︎

  9. Experience | Marshall Beck. LinkedIn. Retrieved December 6, 2024, from https://www.linkedin.com/in/marshall-beck-1308a040/details/experience/ ↩︎

  10. Former Board Members. AllerGen. Retrieved April 22, 2022, from https://www.allergen.ca/about/governance/bod/former-board-members/ ↩︎

  11. AllerGen-NCE Inc Management Team | Org Chart. RocketReach. Retrieved December 6, 2024, from https://rocketreach.co/allergen-nce-inc-management_b70d1adac4ec1e73 ↩︎

  12. Dr. Brandie Walker. (2014, July 25). Canadian Lung Association. http://archive.today/2022.01.09-211927/https://www.lung.ca/lung-research/our-researchers/dr-brandie-walker ↩︎

  13. 2014/2015 Annual Report. Canadian Lung Association. Retrieved May 6, 2022, from https://web.archive.org/web/20160413195706/http://www.lung.ca/file/1172/download?token=B8JBiFLw ↩︎

  14. Soller, L., Abrams, E. M., Carr, S., Kapur, S., Rex, G. A., Leo, S., Lidman, P. G., Yeung, J., Vander Leek, T. K., McHenry, M., Wong, T., Cook, V. E., Hildebrand, K. J., Gerstner, T. V., Mak, R., Lee, N. J., Cameron, S. B., & Chan, E. S. (2019). First real-world safety analysis of preschool peanut oral immunotherapy. The Journal of Allergy and Clinical Immunology: In Practice, 7(8), 2759-2767.e5. https://doi.org/10.1016/j.jaip.2019.04.010 ↩︎

  15. Tunis, M. C., Dawod, B., Carson, K. R., Veinotte, L. L., & Marshall, J. S. (2015). Toll‐like receptor 2 activators modulate oral tolerance in mice. Clinical & Experimental Allergy, 45(11), 1690–1702. https://doi.org/10.1111/cea.1260 ↩︎

  16. Disclosure statement: Timothy Caulfield. (2021). University of Alberta. https://web.archive.org/web/20221025073517/https://www.ualberta.ca/law/media-library/faculty-research/hli/people/timothy-caulfield/disclosure-statement-2.pdf ↩︎